Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Malignant rheumatoid arthritis].

M Nobunaga1

  • 1Department of Clinical Immunology, Kyushu University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 1, 1992
PubMed
Summary
This summary is machine-generated.

Malignant rheumatoid arthritis (MRA), a severe form of rheumatoid arthritis (RA) with systemic vasculitis, affects 4-5% of RA patients. Advancements in treatment are improving prognosis for this condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum Antibodies to Cytoskeletal Systems in Patients with Adult T-Cell Leukemia and Healthy HTLV-1 Carriers.

Leukemia & lymphoma·2016
Same author

Serum C4 levels in patients with systemic lupus erythematosus in remission.

Modern rheumatology·2014
Same author

Congenital diaphragmatic hernia in identical twins.

Pediatric surgery international·2000
Same author

Serum interleukin-2 receptor for the early diagnosis of rheumatoid arthritis.

Clinical rheumatology·1998
Same author

Induction of drug resistance to gold sodium thiomalate in a monocyte cell line, THP-1.

Clinical rheumatology·1998
Same author

NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus.

Drugs·1997

Area of Science:

  • Rheumatology
  • Immunology
  • Pathology

Context:

  • Malignant rheumatoid arthritis (MRA) is a severe complication of rheumatoid arthritis (RA).
  • It involves systemic vasculitis or severe extra-articular manifestations, potentially leading to fatal outcomes.
  • MRA affects 4-5% of hospitalized RA patients, with a male to female ratio of 1:1.45.

Purpose:

  • To define and describe the characteristics of Malignant Rheumatoid Arthritis (MRA).
  • To outline the histological types, laboratory features, and epidemiological data of MRA.
  • To discuss the recent trends and prognosis of MRA.

Summary:

  • Histologically, rheumatoid vasculitis in MRA presents in three main types: RA type, PN type, and EA type.
  • Characteristic laboratory findings include high rheumatoid factor titers, immune complexes, hypocomplementemia, hypoproteinemia, decreased choline esterase, elevated alkaline phosphatase, and leukocytosis.

Related Experiment Videos

  • Recent observations suggest a decline in MRA incidence and improved prognosis, likely due to therapeutic advancements.

    • Impact:

    • Understanding MRA's distinct features aids in early diagnosis and management.
    • Improved prognosis highlights the effectiveness of contemporary RA treatments.
    • Further research into MRA pathogenesis can lead to targeted therapies.